title: Prognostic factors in continuous hemofiltration therapy for patients with cardiorenal syndrome.
abstract: OBJECTIVE
  The aims of this study were to investigate the efficacy and identify the prognostic factors of continuous hemofiltration in patients with cardiorenal syndrome (CRS) and, finally, to optimally select patients who could benefit more from this therapy.
  
  
  METHODS
  A total of 59 patients with CRS type 1 or type 2 treated with continuous hemofiltration were enrolled. We collected their clinical data and divided them into 2 groups according to their survival or death during hospitalization to conduct a retrospective analysis on factors affecting mortality.
  
  
  RESULTS
  The following items were significantly different between the survival (n = 30) and death (n = 29) groups: serum creatinine, serum total bilirubin, direct bilirubin, white blood cells, hemoglobin, hematocrit, left ventricular end-diastolic diameter, left ventricular end-systolic diameter, systolic blood pressure and mean arterial pressure before hemofiltration, and average dehydration volume during the hemofiltration process. Leukocytosis was a risk factor for death (OR 1.242, 95% CI 1.242-1.480), and elevated sCr was not a key negative factor in the prognosis of CRS (OR 0.994, 95% CI 0.989-1.000).
  
  
  CONCLUSIONS
  Cardiac function before hemofiltration and the amount of dehydration during the hemofiltration process both affected the prognosis. Infection and fluid overload condition at the beginning of hemofiltration were independently associated with mortality during hospitalization.
authors.affiliation: Department of Nephrology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
authors.forename: Xing
authors.initials: X
authors.lastname: Li
authors.forename: Huijuan
authors.initials: H
authors.lastname: Mao
authors.forename: Xiangbao
authors.initials: X
authors.lastname: Yu
authors.forename: Ming
authors.initials: M
authors.lastname: Zeng
authors.forename: Bo
authors.initials: B
authors.lastname: Zhang
authors.forename: Guang
authors.initials: G
authors.lastname: Yang
authors.forename: Yifei
authors.initials: Y
authors.lastname: Ge
authors.forename: Yamei
authors.initials: Y
authors.lastname: Zhu
authors.forename: Xianrong
authors.initials: X
authors.lastname: Xu
authors.forename: Changying
authors.initials: C
authors.lastname: Xing
authors.forename: Xiangqing
authors.initials: X
authors.lastname: Kong
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D059347:Cardio-Renal Syndrome / Q000097:blood / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D015897:Comorbidity; D003681:Dehydration; D005260:Female; D006334:Heart Function Tests; D006440:Hemofiltration / Q000379:methods; D017052:Hospital Mortality; D006801:Humans; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome